Acceptance of a Partially Hydrolyzed Formula
Parent And Infant Relief (PAIR): Acceptance of a Partially Hydrolyzed Formula
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Nancy Moore, RD
- Phone Number: 812-429-5000
- Email: nancy.moore@rb.com
Study Contact Backup
- Name: Steven Wu, MD
- Phone Number: 812-429-7564
- Email: steven.wu2@rb.com
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35205
- Birmingham Pediatric Associates
-
Birmingham, Alabama, United States, 35235
- Alabama Clinical Therapeutics
-
-
Florida
-
Miramar, Florida, United States, 33025
- DBC Research USA
-
Sarasota, Florida, United States, 34243
- Proactive Clinical Research
-
-
Illinois
-
Moline, Illinois, United States, 61265
- Mid Valley Research Inc.
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68502
- Frontier Pediatric Research
-
-
South Carolina
-
Charleston, South Carolina, United States, 29414
- Meridian Clinical Research
-
Greenville, South Carolina, United States, 29607
- TRIBE Clinical Research
-
-
Tennessee
-
Memphis, Tennessee, United States, 38115
- AVIATI Healthcare & Clinical Research
-
-
Texas
-
Del Rio, Texas, United States, 78840
- South Texas Pediatric Research Group
-
Edinburg, Texas, United States, 78539
- Proactive Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Primary caregiver has reliable access to the internet and a reliable device (such as a computer, tablet, or smartphone) to access mobile apps and be able to view and complete study questionnaires
- Singleton birth
- 15 to 75 days of age at Visit 1, inclusive (day of birth is considered Day 0)
- Gestational age of ≥37 to 42 weeks (36 weeks and six days is considered 36 weeks' gestational age)
- Birth weight of 2500 g (5 lbs 8 oz) or more
- Exclusively receiving an intact protein infant formula (cow's milk-based or plant-based) for 7 days prior to Visit 1
- Answer to question: "On average, how fussy has your baby been over the past 3 days" is moderately fussy, very fussy, or extremely fussy at Visit 1
- Parent(s) or legal guardian has full intention to exclusively feed study formula during the study period
- Parent(s) or legal guardian agrees not to enroll infant in another interventional clinical study while participating in this study
- Signed informed consent obtained from parent or legal guardian for infant's participation in the study
- Signed authorization obtained from parent or legal guardian to use and/or disclose Protected Health Information for infant from birth through the length of the study period
Exclusion Criteria:
- Infant has been weighed by a health care professional (HCP) and is identified with inadequate weight gain or failure-to-thrive
- Diagnosis or suspicion of cow's milk protein allergy by a healthcare professional
- Any acute illness within the 3 days prior to Visit 1
- Infant has had immunizations or a surgical procedure within the 3 days prior to or on Visit 1
- Immunizations are planned for the infant during any of the 7 days after Visit 1
- Use of oral, intramuscular or intravenous antibiotics within the 7 days prior to Visit 1
- Infant has had bloody stools (visible to the naked eye) within the 7 days prior to Visit 1
- Infant has been taking medication (prescribed and over-the-counter) for gastrointestinal conditions for any of the 7 days prior to Visit 1 (however, probiotics are allowed)
- Infant has a surgical procedure planned during the study period
- History of underlying metabolic or chronic disease; congenital malformation; or any other condition which, in the opinion of the investigator, is likely to interfere with: the ability of the infant to ingest food, the normal growth and development of the infant, or the evaluation of the infant
- History of underlying neurological or organic disease likely to cause fussiness, such as (but not limited to) a doctor's diagnosis of neonatal abstinence syndrome and inflammatory or orthopedic disorders
- Infant is immunocompromised (according to a doctor's diagnosis of immunodeficiency such as combined immunodeficiencies, DiGeorge syndrome, Wiskott-Aldrich syndrome, severe congenital neutropenia and secondary immunodeficiencies linked to HIV infection, Down syndrome or others)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Cow's milk intact protein infant formula
Control
|
Intact cow's milk protein
|
|
Experimental: Partially hydrolyzed cow's milk protein infant formula
Investigational
|
Partially hydrolyzed cow's milk protein
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fussiness
Time Frame: Study Feeding Days 1 through 7
|
Daily Diary
|
Study Feeding Days 1 through 7
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fussiness
Time Frame: Study Feeding Days 8-28
|
Daily Diary
|
Study Feeding Days 8-28
|
|
Study Formula Intake
Time Frame: Study Feeding Day 7 and Study Feeding Day 25 (+3 days)
|
24-hour Recall of Study Formula Intake
|
Study Feeding Day 7 and Study Feeding Day 25 (+3 days)
|
|
Brief Infant Sleep Questionnaire
Time Frame: Study Feeding Day 14 (+2 days) and Study Feeding Day 25 (+ 3 days)
|
Revised Short Form (BISQ-R SF)
|
Study Feeding Day 14 (+2 days) and Study Feeding Day 25 (+ 3 days)
|
|
Quality of Life Questionnaire
Time Frame: Study Feeding Day 7 (+2 days) and Study Feeding Day 25 (+3 days)
|
Pediatric Quality of Life Inventory™ Family Impact Module (PedsQL FIM)-Acute
|
Study Feeding Day 7 (+2 days) and Study Feeding Day 25 (+3 days)
|
|
Medically confirmed adverse events
Time Frame: Day 1 through end of feeding
|
Collected from medical records
|
Day 1 through end of feeding
|
|
Gassiness
Time Frame: Study Feeding Days 1-28
|
Daily Diary
|
Study Feeding Days 1-28
|
|
Crying
Time Frame: Study Feeding Days 1-28
|
Daily Diary
|
Study Feeding Days 1-28
|
|
Spit-up
Time Frame: Study Feeding Days 1-28
|
Daily Diary
|
Study Feeding Days 1-28
|
|
Sleep
Time Frame: Study Feeding Days 1-28
|
Daily Diary
|
Study Feeding Days 1-28
|
|
Stool frequency
Time Frame: Study Feeding Days 1-28
|
Daily Diary
|
Study Feeding Days 1-28
|
|
Stool consistency
Time Frame: Study Feeding Days 1-28
|
Daily Diary
|
Study Feeding Days 1-28
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 3392-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.